IFNA1 and Hepatic fibrosis: Among the baseline characteristics examined, female gender (p = 0.037), a history of relapse following previous HCV treatment (p = 0.020), HCV genotype 1b (p = 0.001), a HCV VL lower than 800,000 IU/mL (p = 0.016) and IL28B genotype CC at rs12979860 (p = 0.015) were all significantly associated with SVR12, whereas advanced liver fibrosis (p = 0.046), a history of prior null-response to PEG-IFN/RBV (p = 0.008) or the status of prior partial or null-responder to previous HCV therapy (p = 0.001) were all significantly associated to a non-response to triple therapy (Table 2).